• Psyched Wellness (PSYC) ships ‘Calm’ to New York distribution partner Choice Wholesale and retail rollouts are underway
  • The product will be scaled throughout 40 specialized smoke shops within New York City and surrounding areas
  • Psyched Wellness is continuing to focus on its brick-and-mortar expansion
  • Most recently, the company activated two additional entities (TruLife Distribution and Spacestation CPG)
  • Psyched Wellness (PSYC) is down 18.75 per cent, trading at C$0.07 at 10:40 am EDT

The tri-listed company, Psyched Wellness (PSYC) delivers its first shipment of Calm to Choice Wholesale, in the state of New York.

Shipping Calm

The product will be scaled throughout 40 specialized smoke shops within New York City and surrounding areas.

Psyched Wellness Chief Executive Officer Jeff Stevens commented, “There is no bigger and more concentrated market than New York City.”

Stevens went on to add that he is striving for the product to be widely available.

“Our goal was to position Calm in a retailer that is easily accessible with multiple storefronts, has staff that really commit to an intimate understanding of the product, and a customer that is already open to learning about innovative new offerings.”

Our partners at Choice Wholesale did an incredible job delivering a retail environment conducive to both product education and adoption.”

Future outlook

Psyched Wellness is continuing to focus on its brick-and-mortar expansion.

Most recently, the company activated two additional entities (TruLife Distribution and Spacestation CPG).

Going forward, the goal is to push product listings through retailers in addition to the Health, Wellness, and Nutrition sales verticals.

Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products.

Psyched Wellness (PSYC) is down 18.75 per cent, trading at C$0.07 at 10:40 am EDT.

More From The Market Online
stock market down

@ the Bell: TSX hits near-month high

The TSX rose near highs not seen in a month, but a split between indices capped gains as mining and energy were the only…

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.

Cloud DX signs fourth contract with a provincial health authority

Cloud DX (TSXV:CDX) signs its fourth contract with a provincial health authority for remote patient monitoring.

International Petroleum stock rallies on Q1 results

Canadian energy stock International Petroleum Corp. (TSX:IPCO) rose in Tuesday trading on its Q1 2024 financial...